1 résultats
Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung)
Auteurs / Authors
Cortot A B, Madroszyk A, Giroux Leprieur E, Molinier O, Quoix E, Berard H, Otto J, Rault I, Raimbourg J, Hureaux J, Moreau L, Debieuvre D, Morel H, Denis M, Amour E, Morin F, Moro-Sibilot D, Cadranel J
Journal / Conference
ASCO
Année / Year
2019
PMID / session
Poster
Etude IFCT